Parker Waichman LLP

Medtronic Infuse Bone Graft Sales Continue to Sink

It looks like Medtronic’s Infuse Bone Graft troubles are still impacting the medical device maker’s bottom line. Though Medtronic reported a small increase in its third quarter earnings today, its spine business was down 9%, thanks in large part to slowing sales of Infuse, a genetically engineered bone graft product approved for use in certain […]

It looks like Medtronic’s Infuse Bone Graft troubles are still impacting the medical device maker’s bottom line. Though Medtronic reported a small increase in its third quarter earnings today, its spine business was down 9%, thanks in large part to slowing sales of Infuse, a genetically engineered bone graft product approved for use in certain types of spinal fusion surgeries.

“The year-over-year decline is not sustainable. We urgently need to see signs of improvement” in Medtronic’s spine business, Chief Executive Officer Omar Ishrak said on a conference call, according to a report from Reuters. Ishrak declined to say how long it may take for business to improve.

According to Reuters, Medtronic reported net earnings of $935 million, or 88 cents per share, for the third quarter that ended January 27, compared with $924 million, or 86 cents per share, a year earlier. After adjusting for one-time factors, earnings were 84 cents per share, matching the average estimate on Wall Street.

Earnings were also held down by a 9% drop in sales of implantable cardioverter defibrillators, devices used to rapid heartbeats. According to a report from the Pioneer Press, sales of those devices were hurt more than a year ago by a medical study that suggested overuse of the devices followed by word of an investigation by the US. Department of Justice.

For several years now, Medtronic’s Infuse bone growth product, which contains recombinant human Bone Morphogenetic Protein-2 (rhBMP-2), has been the subject of growing controversy. Both the U.S. Justice Department and the U.S. Senate Finance Committee have been conducting ongoing investigations of Medtronic’s marketing of Infuse, and a mounting number of personal injury lawsuits have also been filed by victims of alleged Infuse complications.

The slowing Infuse sales seen in the third quarter could be attributed to yet another medical study that questioned the safety of the spine product. That study, presented in November at the North American Spine Society by Dr. Eugene Carragee, raised worries about a possible association between high doses of rhBMP-2 and an increased risk of cancer. Infuse is often administered at higher-than-approved doses when it is used in off-label procedures.

Carragee, a prominent researcher and spine surgeon with Stanford University, is a long-time critic of Infuse. Over the summer, he published an article in The Spine Journal asserting that Medtronic-paid surgeons had failed to report serious complications from Infuse, including cancer, sterility in men, infections, bone dissolution and worsened back and leg pain. The article said complications occurred in 10 to 50 percent of patients who got the product in 13 Medtronic-funded clinical trials between 2000 and 2010.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Responsiveness , Value Thank you Parker Waichman and a special thanks to Francisco for successfully settling such a complex case like mine. Would refer a friend.
Chulani Sterling
3 years ago
5 Star Reviews 150
I would like to thank both Benita Rollis and Shelly Davis for the wonderful job that they have done for me. They made it easy and helped through the hard times. Thank you both. Steven Lubowsky
Steven Lubowsky
a year ago
5 Star Reviews 150
Positive: Responsiveness I would like to complement my only contact person at your firm. Her name is Ashley Lopitlato her kind reassurances sustained me through times of worry and doubt she made the wait far more bearable. Thank you, Ashley
R Nagle
3 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038